Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06396533 · ClinicalTrials.gov registry record
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
A clinical trial of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- 92
- Enrollment target
- 2
- Study locations
NCT06396533: Recruiting study of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.
NCT06396533 is a study of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 92 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06396533, a study of Urothelial Carcinoma and Muscle Invasive Bladder Urothelial Carcinoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- 92 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned for cystectomy due to bladder cancer will be considered for enrollment based on inclusion and exclusion criteria.
Primary Outcome
Determine the utility of a novel, proprietary combined blood and urinary genomic biomarker (ctDNA and cfDNA) assay in predicting the presence or absence of a muscle-invasive bladder cancer at cystectomy when no disease is identified on systematic endoscopic evaluation (SEE, aka seeT0).
Conditions Studied
Study Locations (2)
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2029-02-23 |
What NCT06396533 shows while recruiting
NCT06396533 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT06396533 reports a single indexed study location in Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06396533 about?
NCT06396533 is a clinical study titled "Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)". This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned fo...
What is the current status of trial NCT06396533?
This trial is currently recruiting. The enrollment target is 92 participants. The study started on 2024-08-13. Estimated completion is 2029-02-23.
What conditions does trial NCT06396533 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma.
Who is sponsoring clinical trial NCT06396533?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06396533 being conducted?
This trial has 2 study locations across Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06396533's enrollment target sits among peer trials
92 40th of 85 higher than 46 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI